Under conventional veterinary protocols, equine soft-tissue injuries — particularly tendon and ligament tears — carry some of the longest recovery timelines in sports medicine. A superficial digital flexor tendon (SDFT) injury typically requires 12 to 18 months of stall rest, controlled hand-walking, and progressive rehabilitation before return to full training. During that period, the tendon heals primarily through fibrous scar tissue rather than true tendon fiber regeneration, which is one reason the reinjury rate is estimated at 43–56% within the first competitive season after return.

Suspensory ligament injuries follow a similar trajectory — often 9 to 14 months for partial tears, longer for complete ruptures. Standard protocols typically include stall rest, cold therapy during the acute phase, controlled hand-walking beginning at 6–8 weeks, and ultrasound-guided monitoring at 90-day intervals.

Emerging regenerative research — including PRP, stem cell therapy, and peptide compounds like BPC-157 and TB-500 — is being studied as a means of accelerating and improving the quality of soft-tissue repair. Published preclinical data consistently shows measurable improvements in healing rate, tensile strength, and tissue quality compared to passive rest alone.

The following dosing parameters appear in indexed, peer-reviewed studies. These are research reference values only — True Wellness does not provide dosing guidance, and all applications require licensed veterinary oversight.

BPC-157 and TB-500 act on different but complementary biological pathways — part of why they appear together in stack rationale literature.

BPC-157 works primarily through upregulation of growth hormone receptors on tendon fibroblasts (Chang CH, 2014), VEGF-driven angiogenesis in damaged tissue (Brcic L, 2010), and direct facilitation of collagen fiber organization. In the Cerovecki (2010) MCL model, BPC-157-treated tissue reached ~85% of healthy tensile strength at Day 28 vs. ~65% in controls.

TB-500 operates through the ILK (integrin-linked kinase) pathway (Bock-Marquette, 2004), promoting cell migration, reducing myofibroblast-mediated scar formation (Ehrlich & Hazard, 2010), and supporting keratinocyte and endothelial cell activity. Its anti-fibrotic profile is particularly relevant where excessive scar formation drives reinjury risk.

The non-overlap of these pathways is the JAWS REPAIR stack rationale: BPC-157 drives new tissue formation while TB-500 limits the scar tissue that would compromise that tissue's mechanical integrity.

Regulatory status varies by compound and is subject to change. The following reflects status as of mid-2025:

Detection window data based on published methodology as of 2025:

FEI maintains the most comprehensive international prohibited substances list under the World Anti-Doping Code framework adapted for equine sport. FEI's Equine Prohibited Substances List is updated regularly and explicitly covers growth factors, peptide hormones, and related compounds including Thymosin Beta-4.

USEF maintains its own Equine Drugs and Medications Program. USEF generally aligns with FEI classifications for horses at FEI-sanctioned events but has independent threshold levels and testing protocols for domestic competition.

State Racing Commissions operate under state authority and vary significantly. Many have adopted ARCI model rules, which classify substances into penalty categories — but specific peptide classifications may differ by state. Researchers in racing contexts should consult the applicable state commission directly.

All three frameworks share one principle: compounds that influence performance are generally prohibited during competition windows regardless of whether specific detection methodology has been established. Absence of a validated test is not regulatory permission.

AMDUCA (1994) permits licensed veterinarians to use FDA-approved drugs in an extra-label manner within a valid VCPR. However, AMDUCA applies to FDA-approved drugs — not to unapproved research compounds like BPC-157 and TB-500.

Research compounds fall outside AMDUCA and into institutional research frameworks. Legitimate veterinary research use typically requires institutional oversight, informed consent from the animal owner, and record-keeping consistent with applicable state veterinary practice acts.

State veterinary boards establish standards of practice within each state. Permissibility of using unapproved research compounds varies — veterinarians should consult their state board guidance and document research rationale, owner consent, and clinical monitoring thoroughly.

The Vasireddi N (2025) systematic review covers 35 peer-reviewed studies published between 1993 and 2024 — the most comprehensive evidence synthesis on BPC-157 published to date. Key findings:

• Consistent positive findings across muscle, tendon, ligament, and bone repair models across multiple independent research groups.
• No serious adverse effects reported across any of the 35 included studies — a significant safety signal for a compound with this volume of preclinical study.
• Mechanistic consistency: GH receptor upregulation, VEGF angiogenesis promotion, and anti-inflammatory activity appear reproducibly across study designs and species.
• Limitations acknowledged: Virtually all evidence is preclinical (primarily rodent models). Large-animal and equine-specific clinical trials remain absent from the literature.

For equine researchers, Vasireddi provides the broadest available evidence summary while underscoring the critical gap in species-specific research.

GHK-Cu is naturally produced in human and animal plasma and declines with age. This endogenous status creates a unique regulatory and analytical profile that distinguishes it from fully synthetic peptides like BPC-157.

Regulatory: Establishing a meaningful "exogenous threshold" for detection is analytically complex — the same challenge faced with endogenous hormones like testosterone in human anti-doping. For equine testing, this methodology is still developing.

Research profile: Pickart's foundational work (2015) documented stimulation of collagen, dermatan sulfate, chondroitin sulfate, and decorin at 1 nM concentrations. PMC:6073405 documented 9× collagen synthesis increase plus MMP and cytokine modulation — relevant to both acute injury and chronic tendinopathy. The Maquart series (1988–1999) demonstrated Type I collagen dominance across multiple delivery formats.

The April 2026 removal of GHK-Cu injectables from the FDA Category 2 restricted list reflects evolving regulatory views on this compound's safety and research applications — though this pertains to compounding pharmacy restrictions, not FEI competition rules.

Biologic therapies (PRP, IRAP, stem cell therapy, ProStride) are the most widely adopted regenerative approaches in equine sports medicine, with the deepest body of equine-specific clinical literature.

Peptide compounds sit in an adjacent space — preclinically robust but equine-clinically early-stage. Mechanism profiles are well-characterized in rodent and in vitro models, but equine-specific dose-response, safety, and controlled clinical outcomes data remain largely absent from the indexed literature. This is where active research interest is concentrated.

Physical modalities (shockwave, laser, PEMF, hyperbaric oxygen) are widely used adjuncts with growing equine-specific evidence bases. Peptide research compounds are increasingly discussed at equine veterinary conferences, driven by the preclinical evidence base and the persistent unmet need in soft-tissue healing outcomes. The field is pre-competitive: researchers are building the evidence infrastructure, not deploying proven protocols.

The 43–56% reinjury rate in equine soft-tissue injuries is not simply a product of premature return to work — it reflects a fundamental biological limitation. Under natural repair conditions, damaged collagen fibers are replaced primarily by Type III collagen (scar tissue) rather than Type I collagen (functional tendon/ligament tissue). Type III collagen has lower tensile strength, less elasticity, and greater susceptibility to re-tear under athletic loading.

This is the mechanism behind reinjury — a horse returns to work with tissue that looks structurally intact on ultrasound but is mechanically compromised at the collagen fiber level. Standard rest-and-rehabilitation protocols improve gross tissue quality but do not resolve the collagen type mismatch.

This is the biological problem that TB-500's anti-fibrotic mechanism (Ehrlich & Hazard, 2010) and GHK-Cu's Type I collagen dominance profile (Maquart, 1988–1999) are designed to address. The research rationale is not simply "faster healing" — it is better-quality tissue that returns the horse to full mechanical integrity rather than scarred approximation. Whether this translates to meaningful clinical improvement at equine-relevant doses remains the central unanswered research question.

• Evidence base is preclinical. All published evidence for BPC-157, TB-500, and GHK-Cu is predominantly from rodent models and in vitro studies. No controlled equine clinical trial data exists as of mid-2025.
• No equine dose-response data exists. Translating rodent study doses to equine-relevant doses requires pharmacokinetic modeling not yet published.
• Regulatory exposure is real. BPC-157 and TB-500 are listed on FEI and USEF prohibited substance lists. Research involving competition horses must account for applicable withdrawal periods and the absence of validated withdrawal time data.
• Informed owner consent is essential. The experimental nature of the protocol, known and unknown risks, and regulatory implications for competition eligibility must be clearly communicated.
• Documentation matters. Compound source, lot number, CoA verification, dose, route, frequency, clinical monitoring, and outcomes should all be recorded. This protects the veterinarian and advances the field.
• Compound quality is a prerequisite. Research-grade compounds from verified sources with third-party CoA documentation are the baseline for any legitimate research application.

Initiate angiogenesis and structural repair cascade. BPC-157 primary driver — daily subcutaneous or intramuscular proximal to injury site per research model.

• BPC-157 daily (AM)
• TB-500 every 3–4 days
• KPV daily if acute inflammation

Collagen matrix remodeling and fiber alignment. GHK-Cu added to drive extracellular matrix reorganization alongside continued systemic TB-500 support.

• BPC-157 every other day
• TB-500 weekly
• GHK-Cu every 3 days

Long-term tissue quality and recurrence prevention. Taper frequency. Monitor via diagnostic panels (EQ-001/EQ-002) to track biomarker normalization.

• BPC-157 2× weekly
• TB-500 bi-weekly
• GHK-Cu weekly